Nuvalent/$NUVL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nuvalent
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ticker
$NUVL
Sector
Primary listing
Employees
218
Headquarters
Website
Nuvalent Metrics
BasicAdvanced
$7B
-
-$5.32
1.30
-
Price and volume
Market cap
$7B
Beta
1.3
52-week high
$104.90
52-week low
$55.54
Average daily volume
538K
Financial strength
Current ratio
10.734
Quick ratio
10.579
Profitability
Effective tax rate (TTM)
-0.16%
Management effectiveness
Return on assets (TTM)
-22.96%
Return on equity (TTM)
-38.79%
Valuation
Price to book
8.2
Price to tangible book (TTM)
8.2
Price to free cash flow (TTM)
-26.048
Free cash flow yield (TTM)
-3.84%
Free cash flow per share (TTM)
-3.68
Growth
Earnings per share change (TTM)
52.21%
3-year earnings per share growth (CAGR)
52.20%
What the Analysts think about Nuvalent
Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.
Bulls say / Bears say
Nuvalent announced pivotal Phase 1/2 ARROS-1 results with a 44% overall response rate (ORR) and responses lasting up to 18 months in TKI pre-treated ROS1-positive NSCLC, underscoring strong clinical potential for NVL-520.
The company has started a rolling NDA submission for zidesamtinib under the FDA’s Real-Time Oncology Review program, aiming for completion in Q3 2025, which could speed up its time to market.
As of June 30, 2025, Nuvalent had approximately $1.0 billion in cash, cash equivalents, and marketable securities, providing enough funding to operate into 2028 and support late-stage trials without an urgent need for more capital.
Nuvalent's net loss for the second quarter of 2025 widened to $99.7 million (GAAP), showing substantial pre-commercial operating losses and a rising cash burn before any product revenue.
R&D expenses rose sharply to $80.9 million in Q2 2025, up 64.6% year-over-year, which raises concerns over persistently high spending prior to reaching commercialization milestones.
The Phase 3 ALKAZAR trial directly compares NVL-655 with Roche’s alectinib in first-line ALK-positive NSCLC, putting NVL-655 in a tough competitive situation where it must show clear advantages to capture market share.
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Nuvalent Financial Performance
Revenues and expenses
Nuvalent Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvalent stock?
Nuvalent (NUVL) has a market cap of $7B as of November 07, 2025.
What is the P/E ratio for Nuvalent stock?
The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of November 07, 2025.
Does Nuvalent stock pay dividends?
No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Nuvalent dividend payment date?
Nuvalent (NUVL) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvalent?
Nuvalent (NUVL) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.